#biotech #Netherlands #GenScript #Delft #mRNA

GenScript's European mRNA Hub: A Game Changer in Biotech

GerScript, a leading player in biotechnology, has officially inaugurated its first European mRNA production facility, strategically located in Delft, the Netherlands. This landmark development not only expands the company's global mRNA platform but also emphasizes Europe’s status as an integral component of its integrated research and production network.

The new site in Delft aims to reinforce GenScript's transatlantic biotech capabilities, granting regional innovators improved access to next-generation therapies, vaccines, and advanced biologics. By establishing this facility, GenScript will enhance the proximity, regulatory compliance, and supply chain safety for biotech companies operating in Europe.

Dr. Paula Río from the CIEMAT/CIBERER/FJD research and development unit noted the advantages of having a local GenScript facility within the EU. “Having a local presence allows faster collaboration, less shipping delay, and better alignment with EU regulations,” she expressed. This highlights GenScript's commitment to making biotech collaboration more efficient and reliable, while also showcasing its broader strategy of embedding global capabilities into local infrastructures.

GenScript, founded over two decades ago in New Jersey, has consistently sought to bolster its innovation footprint across North America and Europe. By establishing its European headquarters in the Netherlands in 2021, the company set the foundation for its ongoing expansion, which has now culminated in the opening of the Delft facility. Shawn Wu, President of GenScript’s EU Division, remarked, “Europe is not merely an outpost for us; it is fundamentally a core component of our global mRNA strategy.” This commitment underscores the company's aim to provide faster, synchronized operations for its partners while ensuring uniform global standards across all locations.

Advanced Facilities and Services

The Delft site has been integrated into one of Europe’s most promising life science ecosystems, capable of executing a complete mRNA workflow which includes:

• - Gene Design and Synthesis
• - Vector Engineering
• - IVT mRNA Production
• - Proprietary GenCap™ mRNA Capping Technology
• - UTR Optimization and Formulation Support

This facility adopts GenScript’s AI-enabled digital operating model, enhancing operational consistency and accelerating turnaround times for biotechnology projects. By adhering to EU regulatory requirements while being connected to GenScript’s worldwide quality control systems, the Delft site enables its clients to transition efficiently from research-grade mRNA to various developmental approaches.

The opening of this site follows GenScript's ongoing expansion efforts in the United States, particularly at its New Jersey campuses, as the company seeks to create a comprehensive global presence. These investments reflect GenScript's commitment to fostering robust and high-quality growth platforms that can facilitate innovation in the life sciences sector from the earliest stages of discovery to advanced development.

Addressing Europe’s Biotech Aspirations

GenScript's establishment in Delft not only enriches its operational landscape but also directly supports the innovation ambitions of the European biotech community. Collaborators and partners within this ecosystem, such as Planet B.io, have expressed optimism over this partnership. Cindy Gerhardt, Managing Director of Planet B.io stated, “The opening of this cutting-edge facility solidifies the Biotech Campus Delft’s significance, creating advantages for both our local community and the broader European biotech sector.”

This expansion, according to Sherry Shao, CEO of GenScript Biotech Corporation, demonstrates the continued execution of their global platform strategy that seeks to enhance the potential of biotechnology on a worldwide scale. “At GenScript, our mission—‘Scripting Possibilities’—exemplifies our dedication to constructing integrated systems that facilitate moving from scientific discovery to practical development seamlessly across regions.”

Thus, with the launch of its Delft facility, GenScript marks a pivotal step forward in its journey towards advancing the future of mRNA innovation and solidifying its presence in Europe’s dynamic biotech landscape.